BONESUPPORT HOLDING AB (publ) – Publishes Q2 2023 interim report

MAR

BONESUPPORT HOLDING AB (publ), a leading company in orthobiologics for the management of bone injuries, today publishes the interim report for the second quarter 2023.

STRONG MOMENTUM FOR CERAMENT G IN THE US

APRIL – JUNE 2023

  • Net sales increased by 88 percent (75 percent at constant exchange rates) and amounted to SEK 140.4 million (74.6).
  • The North America (NA) segment reported a sales growth of 126 percent (107 percent at constant exchange rate).
  • The Europe & Rest of the World (EUROW) segment reported a sales growth of 28 percent (24 percent at constant exchange rates).
  • The gross margin amounted to 91.3 percent (89.0).
  • Operating result before effects from the Group’s incentive programs amounted to SEK +13.6 million (-9.1). Reported operating result amounted to SEK +6.0 million (-14.9).
  • Earnings per share before dilution were SEK +0.08 (-0.25).
  • Earnings per share after dilution were SEK +0.08 (-0.25).

JANUARY – JUNE 2023

  • Net sales increased by 85 percent (72 percent at constant exchange rates) and amounted to SEK 260.1 million (141.0).
  • The North America (NA) segment reported a sales growth of 118 percent (100 percent at constant exchange rate).
  • The Europe & Rest of the World (EUROW) segment reported a sales growth of 31 percent (27 percent at constant exchange rates).
  • The gross margin amounted to 90.9 percent (89.7)
  • Operating result before effects from the Group’s incentive programs amounted to SEK +18.2 million (-21.6). Reported operating result amounted to SEK +6.7 million (-31.3).
  • Earnings per share before dilution were SEK +0.09 (-0.51).
  • Earnings per share after dilution were SEK +0.08 (-0.51).

"Strong quarter, with increased market penetration for CERAMENT G." Emil Billbäck, CEO


EVENTS DURING THE REPORTING PERIOD

  • In May, a study was published of 53 patients, with an average follow-up time of 30 months, in which 100 percent of patients were able to avoid amputation when using CERAMENT G/V in the treatment of complex diabetic foot osteomyelitis cases.
  • Strong long-term data with CERAMENT G for severe open fractures were presented in a study from Manchester University Hospital in May. The study was conducted with 81 patients with a mean follow-up time of 55.8 months.

EVENTS AFTER THE REPORTING PERIOD
Nothing to report.

Datum 2023-07-13, kl 08:00
Källa MFN
Bifogade filer
Vill du synas här? Kontakta hej@allaaktier.se. Vår sajt har 100 000 sidvisningar och 10 000 unika besökare per månad. Vår discord har över 5000 medlemmar. Detta är aktiva sparare med ett stort aktieintresse. Behöver du nå ut till denna målgrupp så hör av dig!